問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Medicine

Taoyuan Chang Gung Memorial Hospital of The C.G.M.F. (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

楊政達Yang, Cheng-Ta
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

113Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊政達

List

208Cases

2014-08-01 - 2024-10-17

Phase III

A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3)

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    AZD9291

Participate Sites
11Sites

Study ended11Sites

2018-12-01 - 2024-06-21

Phase I

A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab in Combination With Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non Small Cell Lung Cancer (NSCLC) (MAGELLAN)

  • Condition/Disease

    NSCLC

  • Test Drug

    Durvalumab

Participate Sites
9Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-09-20 - 2023-02-28

Phase II

A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib

  • Condition/Disease

    EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib

  • Test Drug

    Savolitinib/TAGRISSOTM

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2020-08-21 - 2024-03-26

Phase III

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

  • Condition/Disease

    NSCLC

  • Test Drug

    Durvalumab

Participate Sites
7Sites

Recruiting7Sites

2009-02-01 - 2017-05-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated3Sites

Suspended4Sites

2008-01-15 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-12-01 - 2024-10-01

Phase I

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

  • Condition/Disease

    Advanced or Metastatic Solid Tumors With KRasG12C Mutation

  • Test Drug

    D-1553

Participate Sites
4Sites

Recruiting4Sites

2006-10-01 - 2009-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2005-12-01 - 2007-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2010-08-01 - 2011-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 13 14 15 16 17 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB